2023 - Cancer Immunotherapy: Exploring Imaging as a Catalyst to Immune Response Prediction

This webinar delves into three crucial topics related to imaging as a catalyst to predict responses to cancer immunotherapy. The featured speakers critically examine the evolving landscape of immunotherapy, the transformative power of predictive biomarkers and the emerging potential of artificial intelligence (AI) in enhancing the capabilities of radiomics, emphasizing the intricacies and latest breakthroughs in these areas.
Current State of Cancer Immunotherapy Theranostics:
Cancer immunotherapy theranostics are the predictive biomarkers of immunotherapy response. These critical indicators aid clinicians in identifying patients most likely to benefit from immunotherapy and those whose responses may be suboptimal. However, current tissue- or blood-based assays do not encompass all potential patient responses, and even when a beneficial outcome is predicted, a significant percentage of patients do not receive a clinical benefit from immunotherapy, underscoring the need for continued enhancement in predictive capabilities. Dr. Weiss will take attendees through the clinical outcomes and data related to clinically utilized biomarkers for cancer immunotherapy such PD-L1, TMB, MSI and MMR in selected cancer types, along with insights into Quibim’s experiences with cancer immunotherapy imaging classifiers.
Join this webinar to discover the present and transformative impact of predictive biomarkers on immunotherapy response, the role of cytotoxic T cells expressing CD8 in the anti-cancer immune response and the emerging field of radiomics and its potential merger with AI with a discussion on the promising opportunities this fusion presents for complex response assessments in immunotherapy.